Publication | Closed Access

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

ImmunologyClinical TrialsBiomarker ResultsClinical DermatologyPlacebo-controlled TrialSkin PharmacologyDermatologyExperimental DermatologyImmunotherapyMedicineModerate-to-severe Psoriasis